AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’.
One out of eight men develops prostate cancer. With the support from the Medical Research Future Fund (MRFF) Frontiers Initiative, the goal of the multidisciplinary multi-institutional investigator team is to transform the clinical management of prostate cancer by leveraging leading therapeutic radiopharmaceutical technology paired innovative clinical development and a deep understanding of tumour biology to improve the lives of patients with prostate cancer.
The research program is enabled by AdvanCell’s proprietary (Lead-212) 212Pb alpha isotope production technology along with the delivery of a first-in-field clinical platform trial to accelerate the translation of 212Pb-based targeted alpha therapies, one of the most exciting breakthroughs in cancer treatment.
Dr. Anna Karmann MD PhD, AdvanCell Chief Medical Officer said: "On behalf of all Co-Investigators, I would like to thank the Australian Government and MRFF Frontiers Initiative committee for this prestigious award. Targeted alpha therapies are among the most promising in oncology. We believe this MRFF-funded research can be practice changing and have a lasting positive impact on the lives of patients with prostate cancer. We highly value the support and opportunity this funding provides to fast-track translation and accelerate the development of novel combination therapies in an industry-academic partnership."
AdvanCell is collaborating with world-leading experts in Australia and globally, underpinning the transformative nature of the important clinical research. The clinical PIs include internationally renowned physician scientists Prof. Louise Emmett (St Vincent’s Hospital, Sydney and University of New South Wales) and Prof. Shahneen Sandhu (Peter MacCallum Cancer Centre, Melbourne).
Prof. Louise Emmett: "This collaborative Frontiers grant gives us the tools to deeply evaluate optimal combinations with targeted alpha therapy in prostate cancer – aiming for longer better lives using great technology in a smart way."
Prof. Shahneen Sandhu: "Our MRFF grant will accelerate the development of innovative targeted alpha therapy combinations designed to enhance patient care and clinical outcomes."
Scientific investigators include Prof. Richard Payne (The University of Sydney), Prof. Matt Trau, Dr. Alain Wuethrich, Dr. Kevin Koo (The University of Queensland), Dr. Scott Lovell (University of Bath), A/Prof. Serigne Lo (Melanoma Institute Australia) and Dr. Thomas Kryza and Dr. Simon Puttick (AdvanCell).
Prof. Stephen Rose, Head of Translational Medicine and Clinical Science at AdvanCell, highlighted the importance of the MRFF funding. "The MRFF funding supports Australian innovation to drive the establishment of sovereign manufacturing capabilities to accelerate clinical translation of 212Pb-targeted alpha therapy."
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250413421557/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lightbits Labs Closes Q1-2025 with Record-Breaking Growth15.4.2025 15:01:00 CEST | Press release
Accelerated demand for infrastructure modernization modeling hyperscale architecture and AI-ready storage playing a pivotal role Lightbits Labs (Lightbits®), the inventor of the NVMe® over TCP protocol offering next-gen software-defined storage for modern workloads, today announced record-breaking growth for Q1’25. This milestone reflects strong global demand for infrastructure modernization that models Cloud Operations enabled by high-performance block storage offering flexibility, reliability, and cost-efficiency at scale. The breakout quarter for Lightbits, marked by a 4.8X increase in software sales and a 2.9X increase in average deal size, is fueled by a surge in new customers and strong customer loyalty, as evidenced by an impressive 2X YoY license increase. New account growth was particularly strong among financial services, service providers, and e-commerce organizations who require high-performance, low-latency at massive scale. A strong standout use case for Lightbits was amo
NIQ Unveils BASES AI Screener: Helping CPG Brands Thrive in the Age of Hyper-Innovation15.4.2025 15:00:00 CEST | Press release
A real-time, AI-powered idea screening tool built for today's fast-paced innovation cyclesSynthetic survey panels offering quick, low-cost idea testingCombines NIQ panel data with Generative AI to deliver consumer insights reflecting real market trends NielsenIQ (NIQ), a leader in consumer intelligence, officially launched BASES AI Screener, combining NIQ's expansive consumer panel datasets, extensive innovation database, and leading predictive models with AI's ability to mimic human reactions for idea screening. BASES AI Screener is now available in multiple markets, including the United States, United Kingdom, Germany, Brazil, and Indonesia, with continuing expansion in 2025. To meet the evolving needs of today's innovators, NIQ has introduced—BASES AI Screener—a real-time idea screening platform powered by Generative AI (GenAI). By leveraging NIQ's extensive behavioral data from consumer panels, the tool creates synthetic respondents with distinct demographic and purchasing behavior
Perplexity Partners With Vespa.ai to Bring its Search Function In-House15.4.2025 15:00:00 CEST | Press release
By building on the Vespa platform, Perplexity delivers leading AI search to millions of users. Today, Vespa.ai– the company behind the leading platform to build and deploy large-scale, real-time AI applications powered by big data– joined Perplexity to announce the AI-powered answer engine’s shift bringing its search feature in-house. The move will significantly enhance the speed, accuracy, and relevance of search results at a scale only made possible on Vespa’s platform. “The recipe: 1. Solve Search. 2. Use it to solve everything else,” said Aravind Srinivas, CEO of Perplexity. Perplexity's innovative approach of direct, sourced answers to search queries relies on a massive and scalable Retrieval-Augmented Generation (RAG) architecture that can efficiently retrieve and process vast amounts of information from the web, internal databases and users’ personal files. By building on Vespa’s platform, Perplexity delivers accurate, near-real-time responses to more than 15 million monthly use
Boomi CEO Steve Lucas Releases New Book: Digital Impact — The Human Element of AI-Driven Transformation15.4.2025 15:00:00 CEST | Press release
New book demonstrates how, through integration and automation, organizations can break down silos, simplify complexity, and create transformative outcomes that benefit people, communities, and the planet Boomi, the intelligent integration and automation leader, today announced the release of Digital Impact: The Human Element of AI-Driven Transformation (Wiley), a bold new book by Boomi Chairman and CEO Steve Lucas. In it, Lucas makes a powerful case for a problem few business leaders are talking about: the AI revolution is doomed to stall unless we first fix the broken digital infrastructure that supports it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415679642/en/ Boomi CEO Steve Lucas Releases New Book: Digital Impact — The Human Element of AI-Driven Transformation With nearly 30 years of leadership at companies including Adobe, SAP, Salesforce, and Marketo, Lucas shares a firsthand playbook for addressing the crisi
Decoding Duchenne Muscular Dystrophy: MRI Study Explores the Relationship Between AMRA’s Muscle Biomarkers and Functional Changes in Individuals With DMD15.4.2025 14:54:00 CEST | Press release
Recent AMRA research examines whether the use of MRI-based biomarkers as surrogate endpoints in DMD clinical trials is feasible, allowing for more informative descriptions of disease severity and progression in DMD Researchers from AMRA Medical, in collaboration with Pfizer, Inc., have recently published a study demonstrating the utility of AMRA’s muscle biomarkers as surrogate endpoints to describe functional changes in participants with Duchenne Muscular Dystrophy (DMD). The study explored changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI) – as well as their relationship to changes in physical performance as described by the North Star Ambulatory Assessment (NSAA) – in order to determine whether MRI-based muscle biomarkers have the potential to detect and quantify clinically meaningful changes in DMD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415308325/en/ AMRA's muscl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom